Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 9,808 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Cancer, Advanced Cancer
Interventions
PX-12
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Greenville, South Carolina • Tyler, Texas
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
2
States / cities
Rochester, Minnesota • San Antonio, Texas
Conditions
Advanced or Refractory Leukemia, Myelodysplastic Syndromes
Interventions
JNJ-26481585
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Conditions
Solid Tumors
Interventions
VX15/2503
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Conditions
Kidney Cancer
Interventions
erlotinib hydrochloride, sunitinib malate, biopsy
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Salem, Oregon
Conditions
NSCLC, Solid Tumors
Interventions
YM155, Carboplatin, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neoplasms
Interventions
Gemcitabine, BAY80-6946, Cisplatin, NaCl, BAY80-6964 fixed dose
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina
Conditions
Lymphoma, Small Intestine Cancer
Interventions
pegylated interferon alfa
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Cervical Cancer
Interventions
cisplatin, pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Jackson, Mississippi + 7 more
Conditions
Immune-related Adverse Events, Advanced Solid Tumor
Interventions
Rituximab, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Conditions
Cancer of the Bile Duct
Interventions
Regorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia
Conditions
Cancer
Interventions
Experimental (Delphi Surveys), Experimental (Focus Groups), Qualitative interviews
Other
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, New York
Conditions
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Interventions
NC525
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Duarte, California • Miami, Florida • Boston, Massachusetts + 6 more
Conditions
Advanced Solid Tumor
Interventions
PM14
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pivanex, Docetaxel
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
5
States / cities
La Verne, California • New Orleans, Louisiana • Brooklyn, New York + 2 more
Terminated Phase 1Phase 2 Interventional Results available

RNActive®-Derived Therapeutic Vaccine

NCT00906243
Conditions
Hormone Refractory Prostate Cancer
Interventions
CV9103
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Tumors
Interventions
E7046
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Solid Tumor
Interventions
FF21101
Biological
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Oklahoma City, Oklahoma + 1 more
Conditions
Melanoma
Interventions
Pembrolizumab and high dose interferon alfa-2b (HDI)
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Buffalo, New York • Pittsburgh, Pennsylvania
Conditions
Advanced Colorectal Adenomas, Adenocarcinoma of the Colon, Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
Interventions
defined green tea catechin extract, placebo, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • Hines, Illinois • Rochester, Minnesota